Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients with Gastric Cancer
Key facts
- Where
- Turku, FinnországSee the site
- Phase
- 2. fázis
Where in Finnország
- Varsinais-Suomen hyvinvointialueTurku, FinnországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Varsinais-Suomen hyvinvointialue
- Trial code
- EU 2026-526494-42-00
- Record updated
- 2026. június 5.
- Original description
1) To assess the accuracy of 18F-FAPI-74 PET/CT in detection of local lymph node or distant metastasis on patient level in patients with primary GC 2) To assess the accuracy of 18F-FAPI-74 PET/CT in assessing the neoadjuvant therapy response among primary GC patients undergoing surgeryRead full original descriptionShow less
1) To assess the accuracy of 18F-FAPI-74 PET/CT in detection of local lymph node or distant metastasis on patient level in patients with primary GC 2) To assess the accuracy of 18F-FAPI-74 PET/CT in assessing the neoadjuvant therapy response among primary GC patients undergoing surgery
Inclusion: Suspected primary or recurrent gastric cancer; Subjects must be male or female aged 18-85 years; WHO performance score 0-2; Subjects must be able and willing to give written informed consent and to comply with the requirements of the study protocol.
Exclusion: Medical conditions prohibiting whole-body PET/CT imaging; Vulnerable study subjects such as described in Finnish law clinical studies (disabled, children, pregnant or breast-feeding women, prisoners) will not be included; Study subject cannot understand the purpose of the purpose of the study.